

Huntington's Disease, Cannabis, and All the **Pharmacology in Between**

a -Wr Professor, Associate Dean of Graduate Studies **Dalhousie University**

r La rar , M.S. ., P .D. Ca Department of Pharmacology **Dalhousie University**

r a, J 16 2015 12:00-1:00 p.m.

Alfond 304 **Biddeford Campus**

Lunch will be Provided

Hosted by: John Streicher, Ph.D.

Sponsored by: The UNECOM Biomedical Sciences Department and the Center for Excellence in the Neurosciences



at Dalhousie University. Eileen's current research interests include the pharmacology of cannabinoids, dopamine, and endothelin, transcriptional regulation, and Huntington's disease. She is currently a member of multiple professional research societies, including the Canadian Society for Neuroscience and an

executive board member of the Canadian Council on Animal Care. Eileen obtained her BSc Hon in Biology and PhD from Dalhousie



r B La rar is a PhD student in the Department of Pharmacology at Dalhousie University. He has published 13 manuscripts in peer-reviewed journals, 24 conference abstracts, and 3 patents. Robert's current research focuses on applying the pharmacological principals of biased agonism and allosteric modulation to the development of novel cannabinoid-based therapeutics. He is the student representative for the International Cannabinoid Research

Society and the American Society for Pharmacology and Experimental Therapeutics – Neuropharmacology Division. Robert obtained his BSc Hon in Biochemistry from the University of Saskatchewan and his MSc in Pharmacology and Neuroscience from Dalhousie University.